Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment

• Shu-Fu Lin,

  Affiliation Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan, ROC

  ⨯
• Jen-Der Lin,

  Affiliation Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan, ROC

  ⨯
• Ting-Chao Chou,

  Affiliation Laboratory of Preclinical Pharmacology Core, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯
• Yu-Yao Huang ,

  * E-mail: yyh@cgmh.org.tw (YH); wongr@mskcc.org (RJW)

  Affiliation Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan, ROC

  ⨯
• Richard J. Wong

  * E-mail: yyh@cgmh.org.tw (YH); wongr@mskcc.org (RJW)

  Affiliation Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

  ⨯